Clinically relevant resistance mutations in the protease gene. The most frequent RT mutations were M184V (n?11), conferring resistance to lamivudine and emtricitabine, and Y181C (n?4), G190A/S (n?4) and K103N (n?4), conferring resistance to NNRTIs. Of concern, three children (16 ; 95 CI: 3 ?40 ) had thymidine analogue mutations, associated with cross-resistance to all NRTIs. Figure 1 gives the pr